Wheat arabinoxylans health benefits

What are the health benefits of arabinoxylans from wheat?

What are the health benefits of arabinoxylans from wheat?

December 10th, 2021

Arabinoxylans are soluble prebiotic fibres extracted from cereal grains, such as the wheat endosperm. Arabinoxylans can be used as dietary supplements or functional food ingredients due to their researched beneficial effects on gut health, glycaemic control and immune health.

Wheat arabinoxylans health benefits

What are arabinoxylans?

Arabinoxylans are soluble fibres extracted from cereal grains. Arabinoxylans have been identified in all major cereal grains, including wheat, barley, oats, rye, rice, sorghum, maize, and millet.

In cereal grains, arabinoxylans are localized mainly in the cell walls of starchy endosperm and the aleurone layer, in the bran tissues, and in the husk of some cereals.

Depending on the genus and species, the amount and structure of arabinoxylans in a particular tissue may vary. For instance, in wheat, there is more arabinoxylan in the walls surrounding the cells of starchy endosperm than in those of aleurone.

Not all arabinoxylans are the same. They vary on the degree of polymerization, which represents the length of the arabinoxylan chains, and on the soluble arabinoxylan content.

As with all fibres, their physicochemical characteristics affect the degree to which they are utilised by the gut microbiota. Higher degrees of polymerization and concentrations of soluble fibre are related to greater bifidogenic effects. [1]

Arabinoxylans can be used as a dietary supplement due to their beneficial effects on gut health, glycaemic control and immune health.

Moreover, due to the physicochemical and technological properties of these molecules (e.g. water-binding capacity, gelation), arabinoxylans can also be used as a baking additive to improve dough consistency, increase loaf volumes and improve crumb structure.

The health benefits of arabinoxylans

Research around arabinoxylans has suggested that these compounds, as part of dietary fibre, have many beneficial physiological effects along the entire human gastrointestinal tract.

These effects are dependent on a complex mixture of molecular and physical properties of arabinoxylan preparations, as well as on the site, rate and extent of their digestion and fermentation in the gut.

• Arabinoxylans have strong prebiotic properties

Arabinoxylans have demonstrated to have prebiotic properties, by selectively stimulating the growth of beneficial bacteria in the colon, such as Bifidobacterium and Bacteroides species. [2,3]

This change in the microbiota is associated with positive health outcomes, such as improved overall health, decreased gut infections and enhanced mineral absorption.

Additionally, the fermentation of prebiotics by intestinal bacteria results in the production of short-chain fatty acids (SCFAs), which have numerous favourable effects.

These effects include the inhibition of harmful bacteria, colon cancer prevention or improvement of glucose tolerance, among others. [4]

• Arabinoxylans improve glycaemic control and insulin sensitivity

Evidence suggests that arabinoxylans from wheat may improve metabolic control in people with impaired glucose tolerance and with Diabetes type 2, by improving blood glucose and insulin levels.

The short-chain fatty acids (SCFAs) formed from the metabolization of arabinoxylans by the gut microbiota are mainly butyrate, acetate and propionate. Acetate and propionate can bind to a specific protein called GPCR43 in the colon.

After binding, the secretion of two peptides (PYY and GLP-1) is increased. This leads to a lowered intestinal motility and a decrease in the levels of a hunger hormone called ghrelin. These processes are key to improving glucose handling. [5,6]

The European Food Safety Authority (EFSA) concluded that there is sufficient scientific evidence to substantiate the health claim that the consumption of arabinoxylans produced from wheat endosperm contributes to a reduction of the glucose rise after a meal. [7]

Some other soluble fibres have also been associated with this health benefit; however, one of the advantages of arabinoxylans lies in their higher palatability.

• Arabinoxylans boost immune health

Arabinoxylans have shown to boost the immune system. Specifically, they may enhance adaptive immunity, innate immunity and gut barrier integrity:

1. Adaptive immunity. Arabinoxylans may enhance vaccination efficacy against influenza, resulting in fewer adverse events, fewer respiratory tract infections and an improved seroprotection rate. [8]

2. Innate immunity. As mentioned, arabinoxylans may promote a beneficial short-chain fatty acid (SCFA) profile. This leads to increased cytokine production, improved monocytes recruitment capacity, and activation of regulatory T-cells, resulting in an increased immune system vigilance. All these cells are involved in keeping the immune system in check by making sure that it returns to a stable state after invaders have been successfully cleaned up. [9,10]

3. Gut barrier integrity. The short-chain fatty acid (SCFA) butyrate provides additional energy to the gut cells and strengthens the mucus layer. Arabinoxylans further induce the upregulation of tight junction proteins, protecting the human body against foreign invaders and strengthening the immune system. [11,12]

How can you add arabinoxylans to your diet?

Arabinoxylans can be found in cereal grains. Arabinoxylan supplements can also be purchased in health food stores and online. They can be found in capsule form, in powder blends or even in bars.

Generally, 1 to 5 grams of arabinoxylans daily are enough to benefit from their prebiotic effect. Regarding EFSA’s health claim on glycaemic control, at least 8% of arabinoxylan-rich fibre produced from wheat endosperm per unit of available carbohydrates should be consumed.

Arabinoxylans are generally considered safe and well tolerated by the gut, meaning that they do not cause intestinal discomfort. [13,14]


What are postbiotics

What are postbiotics? Let's find out!

What are postbiotics? Let’s find out!

December 7th, 2021

Probiotics and prebiotics are very popular nowadays for their positive effects on gut health. Most recently, postbiotics, which are products or metabolites released from microbial fermentation, have also gained attention due to their health benefits. However, they are still unknown to the majority of consumers.

What are postbiotics

What are postbiotics?

Postbiotics are defined as a “preparation of inanimate microorganisms and/or their components that confers a health benefit on the host”. In other words, they are the bacterial products or metabolites released from microbial fermentation.

For this reason, postbiotics include several types of compounds, such as short-chain fatty acids, microbial cell fragments, functional proteins, extracellular polysaccharides, cell lysates or teichoic acid.

Unlike probiotics, postbiotics do not need to be alive to be beneficial, so they are more stable than the living bacteria they are derived from. [1]

Why postbiotics?

Why postbiotics when I can already take probiotics and prebiotics? This may be a question that comes up.

It is important to understand that gut microbiota composition varies between individuals. This means that the degree to which different components are metabolized may be different among persons.

As a result, probiotics and prebiotics may have different health effects between individuals. Moreover, temporal changes in our gut microbiota composition could also influence the effects of these compounds.

On the other hand, many positive health effects of probiotics and prebiotics are due to the production of components such as short-chain fatty acids, microbial fragments, functional proteins or teichoic acid.

As mentioned before, these components are postbiotics, which means that when postbiotics are taken, these components are directly ingested.

If you want to know more about prebiotics, check this article.

What are the health benefits of postbiotics?

Research suggests that postbiotics may have several health benefits. These include the following:

 

• Modulation of the microbiota. Postbiotics components such as butyrate, a short-chain fatty acid, are beneficial for gut health. [2]

 

• Modulation of the immune system. Butyrate can stimulate the production of T cells in the intestine, which helps control immune responses. Other components such as microbial cell wall fragments can increase the production of cytokines, which are chemical messengers that help reduce inflammation and boost immune responses. [2,3]

 

• Modulation of the metabolism. Propionate, a short-chain fatty acid, can help improve insulin sensitivity and glucose tolerance. On the other hand, butyrate can stimulate the production of an antioxidant called glutathione. [1,2]

 

• Weight loss aid. Short-chain fatty acids may help weight loss through the modification of eating behaviours. This is due to the release of hormones that increase satiety. [1]

 

• Reduction of irritable bowel syndrome (IBS) symptoms. A study in 443 individuals with IBS involving orally administered, heat-inactivated Bifidobacterium bifidum, found that the postbiotic substantially alleviated symptoms associated with IBS, such as abdominal pain or discomfort, abdominal bloating and abnormal bowel habits. [4]

 

• Other potential benefits. Orally administered, inactivated lactic acid bacteria may help eradicate Helicobacter pylori infection, chronic unexplained diarrhoea and the abrogation of the negative effects of stress. [1]

How can I add postbiotics to my diet?

Postbiotics are not as easy to find as probiotics and prebiotics, but they can be purchased in health food stores and online. They are generally considered safe and well-tolerated.

As postbiotics are generated from fermentation by the bacteria in your gut, you can increase postbiotics production by eating foods rich in probiotics and prebiotics. Probiotics can be found in fermented foods and drinks, such as yoghurt, kefir, tempeh or kombucha. Prebiotics can be found in high fibre foods, such as vegetables and whole-grain products.


A new study with Olecol® on attenuating sugar digestion and absorption has been published in a peer reviewed scientific journal.

A new study with Olecol® on attenuating sugar digestion and absorption has been published in a peer reviewed scientific journal.

Maastricht, The Netherlands, April 17th, 2018

Press release

The European Journal of Nutrition has published the results of the latest in-vitro and human studies with Olecol®. Olecol® attenuates post-prandial glucose spikes in healthy volunteers through the inhibition of sucrose hydrolysis and glucose transport by oleuropein.

Clinical & In-Vitro benefits of Olecol®

Oleuropein is a major constituent of olive leaves, many studies have shown the beneficial effect on various factors related to diabetes and cardiovascular development. Olecol® is standardized in oleuropein content, highly water-soluble and has already shown in two clinical studies to improve blood lipid profiles in subjects with dyslipidaemia.

The latest research on Olecol® conducted by research of Prof. Gary Williamson from University of Leeds in collaboration with BioActor, evaluated the effect of Olecol® on sugar digestion and absorption.

The researchers at Leeds University first conducted in-vitro experiments to study both carbohydrate digestion enzymes and sugar transporters in vitro. This research demonstrated how these mechanisms can positively modulate postprandial glucose in healthy volunteers consuming different types of carbohydrate. Subsequently, another in vitro study showed that Olecol® inhibited intestinal maltase, human sucrase, glucose transport across Caco-2 monolayers cells, and uptake of glucose by GLUT2 in oocyte cells.

Seven cross-over controlled randomized intervention studies, were performed on young healthy volunteers. Five minutes after either placebo or Olecol® intake, participants were given 109g of white bread (containing 50 g of available carbohydrates). It was shown that the combined action of Olecol® on sucrase and on glucose transport can lead to a significant decrease in peak glucose in healthy volunteers.

The multiple benefits of Olecol® are: improvement of blood lipid control in both subjects with hypercholesterolemia and overweight, strong antioxidant proprieties and attenuation of post- prandial sugar peaks in healthy subjects.

 

About BioActor

BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

Feel free to contact us via info@bioactor.com for more information on the possibilities Olecol® has to offer.
Further information can be found on: www.olecol.com


Metabolic Syndrome

BioActor receives EUROSTARS grant for the FlaMeS project “Flavonoids and metabolic syndrome”

BioActor receives EUROSTARS grant for the FlaMeS project “Flavonoids and metabolic syndrome”

Maastricht, The Netherlands, October 22th, 2012

Press release
BioActor leads the international FlaMeS-consortium to develop novel in-vitro cell technology and clinical validation of Cordiart® for the prevention of the metabolic syndrome. The FlaMeS consortium is a collaboration between two innovation driven SMEs, BioActor (Netherlands) and AdipoPhyt (France). The project will result in the development and clinical validation of novel 3-D cell assays for adipose tissue development and in the clinical validation of a proprietary citrus flavonoid extract for the improvement of glycaemic control and endothelial function.

Metabolic Syndrome

The FlaMeS project

BioActor BV announced today that EUREKA has approved the FlaMeS project, submitted by BioActor and AdipoPhYt. The FlaMeS Consortium has two objectives: (1) validating novel 3-D cell-based assays to screen for effects of compounds on adipose tissue development, and (2) clinically test and validate effects of Cordiart®, a citrus peel extract, on markers associated with the metabolic syndrome.

Prevalence of obesity and the metabolic syndrome is rapidly increasing, affecting millions of people in Europe alone. Public health authorities have recognized the need for prevention of these chronic diseases. BioActor addresses this need by developing a unique, natural product for improved functioning of blood vessels, glycemic control and heart health: Cordiart®.

Cordiart® is a natural flavonoid citrus peel extract with optimized bioavailability. This ingredient commands a high content of natural bioactive flavonoids. A number of in-vivo and human studies have shown very promising effects for Cordiart® in use for blood vessel function, glycemic control and heart health.

In order to test novel substances regarding their effects on adipose tissue (fat storage cells), new ‘humanized’ in vitro models are needed. AdipoPhYt is currently developing a cutting edge new technology “AdipoGut”, combining all present techniques and knowledge into a high quality and predictive test system. The FlaMeS project will result in a marketable functional food ingredient “Cordiart®”, with proven beneficial effects on blood flow, glycemic control and heart health and a cutting edge new in vitro screening technology.

“We are very happy with the Eureka/Eurostars commission’s trust in our project, as this clearly shows that they recognize our serious efforts in developing cutting edge food ingredients and food development technology at BioActor and our partner AdipoPhYt. This grant will enable us to further enhance our scientific knowledge on the effects of polyphenols on the human body and validate our product Cordiart®, which may even revolutionize the health market in cardiovascular disease prevention,” says Hans van der Saag, CEO BioActor.

About BioActor

BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

Feel free to contact us via info@bioactor.com for more information on the possibilities Cordiart® has to offer.
Further information can be found on: www.cordiart.com


Wheat arabinoxylan extract

BioActor acquires Arabinoxylan-assets from DF3-WITAXOS and obtains positive EFSA opinion for its Arabinoxylan ingredient

BioActor acquires Arabinoxylan-assets from DF3-WITAXOS and obtains positive EFSA opinion for its Arabinoxylan ingredient

Maastricht, The Netherlands, April 12th, 2012

Press release
BioActor has acquired patents, know-how and clinical data relating to short-chain wheat arabinoxylans from DF3-WITAXOS. BioActor’s arabinoxylan ingredient obtained positive EFSA opinion for glycaemic control.

Wheat arabinoxylan extract

Arabinoxylan extract from wheat endosperm

BioActor BV announced today that it has acquired certain patents, manufacturing know-how and clinical data from DF3-WITAXOS. Moreover, DF3-WITAXOS’ managing director, Yann Dugenet, has joined BioActor as Director Product Development.

BioActor has already a long-chain Arabinoxylan ingredient derived from wheat endosperm in its portfolio, Naxus®, which recently obtained a positive EFSA Opinion for glycaemic control, and for which promising scientific evidence was recently obtained towards other health endpoints. Hans van der Saag, BioActor’s managing director comments; “The addition of short-chain Arabinoxylans which are derived from the same raw material source as our long chain Arabinoxylans-ingredient, further strengthens our portfolio of patented speciality fibers with clinically proven health effects”.

DF3 WITAXOS obtained excellent clinical data on prebiotic effects of its short-chain Arabinoxylans in a collaborative clinical trial with Institut Pasteur in Lille. Those results were consistent with earlier positive results from in-vitro experiments and in vivo tests on animal models. The integration of this ingredient in the Naxus® range of Arabinoxylan speciality fibers will allow for economies of scale in manufacturing and offers customers more choice in application possibilities.

EFSA has issued a positive opinion for a health claim on glycaemic control in connection with arabinoxylans produced from the wheat endosperm. EFSA proposes the following wording for the health claim: “Consumption of arabinoxylan contributes to a reduction of the glucose rise after a meal”. Naxus® is wheat endosperm derived arabinoxylan, which has been tested in several human studies and directly benefits from this health claim.

Naxus® is also being studied for immune modulation in the context of a 6 million Euro European research project – FIBEBIOTICS –, which is coordinated by Wageningen University (www.fibebiotics.eu).

About BioActor

BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

Feel free to contact us via info@bioactor.com for more information on the possibilities Naxus® has to offer.
Further information can be found on: www.naxus.nl


Wheat arabinoxylan extract

BioActor and Jaeckering sign Joint Development & Marketing Agreement on wheat extract

BioActor and Jaeckering sign Joint Development & Marketing Agreement on wheat extract

Brussels, Belgium/Hamm, Germany, December 1st, 2005

Press release
BioActor and Jaeckering announced today a new collaboration agreement that combines Jaeckering’s know-how to extract bioactives from wheat fractions and BioActor’s know-how in the development and marketing of ingredients for functional food to counteract metabolic syndrome.

Wheat arabinoxylan extract

Collaboration targets novel wheat-based functional ingredients to counteract the metabolic syndrome.

BioActor BVBA (BioActor) and Jaeckering Muehlen-u. Naehrmittelwerke GmbH (Jaeckering) announced today that they have signed a collaboration agreement that combines Jaeckering’s know-how to extract bioactives from wheat fractions and BioActor’s know-how in the development and marketing of ingredients for functional foods. Under the terms of the agreement, BioActor will exclusively market Jaeckering’s innovative pentosan concentrate and parties will actively explore additional opportunities around wheat-based bioactives.JAECKERING in collaboration with Professor Meuser of TU Berlin has developed a proprietary production process to extract wheat pentosans from a starch production sidestream. The resulting soluble fibre product has been validated for its contribution to glycaemic control in humans by the German Institute of Human Nutrition, PotsdamRehbruecke.

According to Hans van der Saag, BioActor CEO, « together with our partner Jaeckering we will exploit the yet untapped potential of wheat for the improvement of human health. We see great opportunities for speciality wheat-based products in combat against metabolic syndrome. Jaeckering’s speciality pentosan concentrate that we will market under the brand NAXUS® has been clinically tested for improved glycaemic control and has excellent food technological properties. Moreover, Jaeckering’s manufacturing prowess acquired over the past 100 years, will greatly help us in developing new and innovative wheat-based health ingredients».

Michel Andreae Jaeckering, CEO of JAECKERING GRUPPE commented that «We are very pleased to have entered into this collaboration with BioActor, a technology company fully focussed on the health ingredients sector. We expect that our collaboration will accelerate the market introduction of our pentosan product and will lead to the introduction of additional new health ingredients».

Jäckering is a major German wheat processor with more than 200.000 tons per annum Wheat grinding capacity and more than 100.000 tons p.a. wheat starch production facilities. Jäckering also produces and markets innovative grinding and drying technology under the brand name ULTRA ROTOR.

About BioActor

BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

Feel free to contact us via info@bioactor.com for more information.